- NewAmsterdam Pharma reported third quarter 2026 revenue of US$19.16 million and a net loss of US$17.39 million, with basic and diluted loss per share from continuing operations of US$0.14.
- The firm’s quarterly revenue and per share loss were better than consensus expectations, indicating tighter cost control and stronger top line traction than analysts had modeled.
- The following section examines how NewAmsterdam Pharma's better than expected US$0.14 loss per share may influence its broader investment narrative.
Compare NewAmsterdam Pharma's earnings surprise with other potential breakout opportunities by scanning our hand picked list of 21 high quality undiscovered gems in similar high-risk and high-reward territory.
NewAmsterdam Pharma Investment Narrative Recap
To own NewAmsterdam Pharma, you need to believe obicetrapib can convert its late stage cardiometabolic and Alzheimer’s programs into a real commercial franchise. The third quarter print, with US$19.16 million in sales and a narrower quarterly loss of US$17.39 million, points to an operation that is starting to build revenue while still firmly in investment mode.
The key near term catalyst remains regulatory progress for obicetrapib in Europe and execution on planned launches with Menarini. The biggest current risk is that operating losses persist if uptake, pricing or reimbursement fall short, especially given ongoing investment and the potential for future equity issuance to dilute existing holders.
The third quarter 2026 report is the clearest recent signal on how NewAmsterdam Pharma is managing this trade off. Revenue for the quarter reached US$19.16 million compared with US$25.91 million for the first nine months. This indicates that a large share of year to date sales came late. The quarterly loss of US$17.39 million contrasted with US$129.97 million for the nine month period.
Those figures matter for the PREVAIL cardiovascular outcomes trial and broader obicetrapib program because they hint at the firm’s ability to fund late stage work and eventual launches without letting expenses run unchecked. For you as a shareholder, the operational question is whether this level of cost control and early commercial traction can be sustained until major readouts and regulatory milestones arrive.
What The Consensus Numbers Assume For NewAmsterdam Pharma
Analysts describe a very specific story around NewAmsterdam Pharma. Their models point to revenue growth of 320.1% each year over the next 3 years, starting from a period where the business is still reporting losses and heavy investment. That pace is very large, so any shortfall in uptake, pricing or reimbursement for obicetrapib would leave a visible gap versus these expectations.
Current earnings are a loss of US$259.5 million. The same group of forecasters expects profits to reach US$81.1 million by 2029 with margins at 15.4% and earnings per share of US$0.47. The shift from a loss of US$259.5 million to earnings of US$81.1 million implies an improvement of roughly US$340 million. This helps explain why there is such a wide spread between the most optimistic and most pessimistic scenarios in the analyst set.
In addition, these projections include annual share count growth of 5.42% over the coming 3 years. The path to per share earnings therefore relies on both operational performance and how much fresh equity NewAmsterdam Pharma issues along the way. The framework uses a discount rate of 7.27% to pull those future cash flows back to today, which influences how much weight the market might put on distant milestones such as the 2029 earnings line.
NewAmsterdam Pharma's narrative projects US$528.0 million revenue and US$81.1 million earnings by 2029. This assumes 320.1% yearly revenue growth and an earnings swing of roughly US$340 million from current earnings of a US$259.5 million loss.
Uncover why NewAmsterdam Pharma's fair value indicates a 170% potential upside to its current price that may not last much longer.
Exploring Other Perspectives
One alternate lens focuses on equity dilution risk rather than PREVAIL. The most bearish analysts were working off revenue of US$181.0 million and earnings of US$28.8 million in 2029, with a high implied P/E of 227.9x. Your view on today’s earnings surprise could shift how credible that more cautious NewAmsterdam Pharma path feels.
Explore 4 other NewAmsterdam Pharma fair value estimates, including one that suggests it could be worth just $49.92!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment results often come from independent thinking, so trust your instincts.
- A great starting point for your NewAmsterdam Pharma research is our analysis highlighting 3 key rewards that could impact your investment decision.
- See our latest analysis for NewAmsterdam Pharma. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate NewAmsterdam Pharma's overall financial health at a glance.
Looking For More Investment Ideas Beyond NewAmsterdam Pharma?
Once you have a handle on NewAmsterdam Pharma's story, it can help to compare it with other opportunities that fit different risk and return profiles using the Simply Wall St Screener.
- For investors who want potential upside without sacrificing financial resilience, you can start with companies that combine cleaner balance sheets with solid fundamentals using our list of solid balance sheet and fundamentals (25 results).
- If your priority is a steadier ride and you prefer businesses with lower overall risk scores, you can narrow the field quickly by scanning our 32 resilient stocks with low risk scores.
- Those hunting for early stage opportunities with room to grow can broaden their watchlist by reviewing the 21 high quality undiscovered gems that meet your preferred quality filters.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com